364 results about "Binding site" patented technology

The invention relates to an organic molecule for the application in optoelectronic devices. According to the invention, the organic molecule hasa first chemical moiety with a structure of Formula I:anda second chemical moiety with a structure of Formula II:wherein W is the binding site of a single bond linking the first chemical moiety to the second chemical moiety,L is selected from a direct bond and a linking group with a structure of Formula BN-I:wherein the dashed lines denote the binding sites as indicated in Formula I, and # represents the binding site of the first chemical moiety to the second chemical moiety.

The invention relates to a UGT enzyme subtype substrate specificity prediction method and model. On the basis of a directional message passing neural network, graph structure characterization of a small molecule compound and features of specific protein binding sites of UGT enzyme are deeply fused, a bimodal prediction normal form of'molecule + protein binding sites' is designed, a deep learning model is constructed, conversion from compound center prediction to molecule-enzyme binding site comprehensive prediction is achieved, and the prediction accuracy is improved. And accurate classification prediction can be carried out on UGT enzyme substrates and non-substrates.

The invention discloses a deep learning prediction method fused with multi-modal features, which can accurately identify protein hidden binding sites in a ligand-free (apoo) state. The method comprises the following steps of: firstly, constructing a protein graph by taking residues as nodes and taking C alpha distance less than or equal to 14 as edges, wherein node feature sets comprise amino acid one-hot, secondary structures, atomic attributes, protein language model embedding and BLOSUM62 evolutionary information, and edge features comprise distance and angle similarity; then capturing three-dimensional geometric equivariant features by adopting an equivariant graph neural network (EGNN), and modeling a chemical topological relation by using a graph isomorphic network (GINE) with edge features; eGNN and GINE double-branch feature fusion and global dependence integration are realized through gating cross attention and gating multi-head attention; and finally, inputting the fusion features into a Kolmogorov-Arnold network (KAN) classifier, and predicting whether each residue belongs to a hidden binding site or not. The method can adapt to large-scale conformation change without coordinate alignment, AUC and F1 on a standard data set are remarkably superior to those of an existing method, high robustness and generalization are kept for multi-chain protein and complex conformation, and the method can be widely applied to drug target discovery and structure-driven drug design.

Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.

The invention discloses injection type facial filler composition gel for medical beauty as well as a preparation method and application of the injection type facial filler composition gel, and belongs to the technical field of biomedical materials. The composition gel comprises a combined gel matrix and polycaprolactone microspheres, wherein the combined gel matrix comprises an aqueous solution for injection, sodium carboxymethyl cellulose and human recombinant collagen; according to the composition gel, a combined gel matrix and polycaprolactone microspheres are mixed according to a specific proportion, amino acid residues of human-derived recombinant collagen in the combined gel matrix serve as binding sites of cell surface receptors to improve the cell recognition and attachment capacity of the polycaprolactone microspheres, and the amino acid residues are organically combined with sodium carboxymethyl cellulose to improve the cell recognition and attachment capacity of the polycaprolactone microspheres. The durability and biocompatibility of the shaping effect of the human-derived recombinant collagen at the injection site are improved; the composition prepared by the invention is good in gel fluidity, high in elastic modulus and high in dynamic viscosity, and can meet the expected mechanical and rheological properties of a facial filling agent for cosmetic and plastic surgery.

The present invention relates to: a receptor tyrosine kinase like orphan receptor 1 (ROR 1) antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector carrying the nucleic acid; a host cell transinfected with the recombinant expression vector; a method for preparing the antibody or the antigen-binding fragment thereof; a bi- or multi-specific antibody bearing the antibody or the antigen-binding fragment thereof; an immune cell-engaging bi- or multi-specific antibody; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) containing the scFv of the antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a composition for combination therapy including the antibody or the antigen-binding fragment thereof; a composition for preventing or treating cancer; and a method for preventing or treating cancer.

An engineered producer cell comprising an inactivating mutation in one or more endogenous REP binding sites is provided, as are methods for producing the engineered producer cell and using the engineered producer cell to produce a recombinant viral vector and reduce producer cell genomic DNA contamination of a recombinant adeno-associated virus vector preparation.

Provided are a method for constructing a soluble expression plasmid mutant library, and the use thereof. The method for constructing the soluble expression plasmid mutant library comprises: introducing mutations into a ribosome binding site on a soluble expression plasmid, a sequence composition and length of a region between the ribosome binding site and an initiation codon of a fusion protein to be expressed, and a translation initiation region, so as to obtain a mutant library. By means of the method, plasmid mutants with increased expression levels are obtained, thereby increasing the expression level of a target fusion protein and the final yield of a target polypeptide. The present invention solves the problem of low soluble expression levels of certain polypeptides in Escherichia coli.

This invention generally relates to a novel RNA / mRNA production and amplification method using viral RNA replicase and / or RNA-dependent RNA polymerase (RdRp) enzymes as well as the associated mRNAs thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA / mRNA sequences carrying at least an RdRp-binding site in the 5′- or 3′-end, or both. The RNA / mRNA so obtained is useful for not only producing mRNA vaccines and / or RNA-based medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase-mediated RNA / mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and / or bacteriophage RNA-dependent RNA polymerases (RdRp), particularly coronaviral and hepatitis C viral (HCV) RdRp enzymes.

The invention provides a simple and rapid preparation method of a novel HER2 targeted nano-drug maytansine (DM1). The preparation of the nano-drug is realized by using carboxyl on a side chain of azide-terminated poly (L-glutamic acid) (PLG) as a load binding site. The preparation method comprises the following steps: firstly, grafting N-(2-aminoethyl) maleimide hydrochloride (Mal-C2H4-NH2-HCL) to carboxyl of PLG (Poly L-Glycol), and introducing a maleimide group to form PLG-Mal; the preparation method comprises the following steps: preparing Fc-III-4C peptide-PLG-Mal (Fc-PLG-Mal) by virtue of an amidation reaction between carboxyl and amino of the Fc-III-4C peptide, and then carrying out thiol-maleimide click chemical reaction on a maleimide group and sulfydryl of DM1, so as to obtain the Fc-PLG-DM1. Finally, the HER2 antibody and the Fc-PLG-DM1 are mixed in water by utilizing the high affinity effect between the Fc-III-4C peptide and the Fc segment of the HER2 antibody, so that the HER2-PLG-DM1 can be obtained, and the HER2-PLG-DM1 has a remarkable tumor inhibition effect in animal experiments. The successful development of the HER2-PLG-DM1 proves the potential of the method in the design and development of functional nano-drugs in the future.

Multi-scale footprinting of DNA-protein interactions is described. Multi-scale footprint scores may be generated based on chromatin accessibility data, the multi-scale footprint scores indicating protein binding to positions of a genome at different protein size scales. A deep learning model may be trained using the multi-scale footprint scores and corresponding DNA sequences. DNA-protein interactions for a DNA sequence of interest may be predicted using the trained deep learning model. The prediction may include generating sequence attribution scores for the DNA sequence of interest using the trained deep learning model and predicting transcription factor binding sites of the DNA sequence of interest based on the sequence attribution scores.

Embodiments of the present disclosure relate to a method for molecular docking and an electronic device. The method comprises: determining a first binding site on a first molecular surface of a first molecule and a second binding site on a second molecular surface of a second molecule based on a first time-dependent multi-scale feature of the first molecule and a second time-dependent multi-scale feature of the second molecule; obtaining a first chemical feature of the first binding site and a second chemical feature of the second binding site; determining a functional mapping matrix between the first chemical feature and the second chemical feature through functional mapping; determining a correspondence between the first binding site and the second binding site based on the functional mapping matrix; and docking the first molecule and the second molecule through the first binding site and the second binding site based on the correspondence. In this way, the molecular docking scheme does not need to be implemented through a large number of samplings, and therefore the three-dimensional structure generated after docking can be determined more quickly and more efficiently.

The present disclosure provides a quantum dot ligand, a quantum dot-ligand system and a quantum dot material, belonging to the field of display technology. The quantum dot ligand includes an X group, a Y group and a Z group. The Y group is configured to provide at least two binding sites, among which at least one binding site is configured to bind with the X group, and the remaining binding site is configured to bind with the Z group. The X group is a coordination group configured to form a coordination bond with a surface of a quantum dot. The Z group is a saturated 3- to 5-membered heterocyclic group containing O or S.

The invention discloses a preparation method and application of a pyrenyl imine covalent organic framework material, and belongs to the technical field of materials. The preparation method comprises the following steps: dissolving 4, 4 ', 4', 4 ''-(pyrene-1, 3, 6, 8-tetrayl) tetraphenylamine and 3, 3 '-dimethoxy-[1, 1'-biphenyl]-4, 4 '-diformaldehyde in an organic solvent, fully mixing, and adding a catalyst to obtain a mixed solution; and freezing the mixed solution with liquid nitrogen, exhausting air, removing oxygen, carrying out a heating reaction, obtaining a yellow precipitate after the reaction is finished, and carrying out filtering, washing and vacuum drying treatment to obtain the pyrenyl imine covalent organic framework material. Pyrenyl and imine bonds on the pyrenyl imine covalent organic framework material structure prepared by the invention can provide a large number of binding sites bound with iodine, and the pyrenyl imine covalent organic framework material has the advantages of high crystallinity, large specific surface area, strong stability and the like, and can be used as a solid adsorption material for effective iodine vapor adsorption.

The invention provides a method for high-throughput screening of an alpha-glucosidase inhibitor from boxthorn leaves based on a multi-shell MOF immobilized enzyme, and aims to overcome the bottlenecks of low throughput, tedious operation, high cost and the like of a traditional screening method. The core process of the method comprises the following steps: preparing a boxthorn leaf sample solution and pre-evaluating the in-vitro alpha-glucosidase inhibitory activity; a multi-shell MOF immobilized enzyme technology is coupled with a UPLC-QTOF-MS / MS technology, so that targeted screening, efficient separation and accurate identification of active components are realized; verifying the alpha-glucosidase inhibitory activity of the target compound; and predicting the binding site of the small molecule compound and the enzyme through a molecular docking technology. The method has the core advantages of high specificity, high sensitivity, high flux, repeated utilization of enzyme receptors and the like by depending on the inherent characteristics of an immobilized enzyme technology, can synchronously screen and identify various inhibitors, effectively integrates the resource advantages of a boxthorn leaf natural product and the high efficiency of a modern high-flux screening technology, and has a wide application prospect. And a key technical support is provided for diversified development of diabetes treatment medicines.

Provided are a novel antithrombotic antibody targeting a blood coagulation factor FIXa-FVIIIa binding site and an application thereof.SOLUTION: The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts an antithrombotic effect. The antibody of the present invention has an appropriate antithrombotic performance and a large effective therapeutic concentration window, but does not increase the bleeding risk, which can achieve the need for moderate antithrombosis and effectively avoid the bleeding problem caused by excessive action in clinical applications. The present invention also discloses methods of screening for drugs that target the FIXa-FVIIIa binding site.SELECTED DRAWING: Figure 1A

The invention provides a preparation method of a biological sample for diamond near-surface quantum sensing, and belongs to the field of quantum sensing detection. The method comprises the steps that a single-layer DNA origami structure is prepared, the single-layer DNA origami structure is provided with a pre-designed biological sample binding site, and the biological sample binding site is coupled with a biological sample through an interaction molecule pair; after the surface of the diamond is subjected to planarization pretreatment through plasma etching, nitrogen ions are injected to form an NV color center, and the diamond containing the NV color center is obtained; in a buffer solution environment containing cations, a solution containing the single-layer DNA origami structure and a to-be-detected biological sample solution are sequentially added to diamond for incubation, and the biological sample for diamond near-surface quantum sensing is obtained. The sample preparation method provides a reliable and efficient sample preparation basis for high-sensitivity and high-specificity single molecule / single particle biological sample detection based on diamond near-surface quantum sensing.

Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.

To provide compounds of the cyanine family having near-infrared emission exhibiting improved physicochemical and biological properties, and to provide conjugates thereof with biological ligands.SOLUTION: Cyanine derivatives of Formula (I) are provided. It may be suitably conjugated to an appropriate targeting moiety via an appropriate functional group which acts as a site of attachment.SELECTED DRAWING: None

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

The application discloses a method and system for predicting protein drug binding sites based on a multi-modal dynamic graph, comprising: obtaining amino acid sequence data and three-dimensional structure data of a protein, and generating evolutionary conservation features, structure graph topology features and sequence features respectively; inputting the features into a multi-modal fusion encoder to generate first fusion features; inputting the first fusion features into a prediction decoder to generate initial prediction probabilities; iteratively updating the structure graph topology features according to a preset three-graph update rule according to the initial prediction probabilities and residue dynamic communication scores; re-inputting the updated structure graph topology features into the multi-modal fusion encoder and the prediction decoder, and repeatedly executing until a preset iteration number is reached, to generate final prediction probabilities; and generating a residue importance heat map and outputting a prediction report based on the final prediction probabilities through a gradient weighted class activation mapping algorithm. The application realizes the cooperative optimization of prediction and graph structure, and significantly improves the accuracy of binding site prediction.

The invention discloses a method for improving the water-resistant straw-like dwarf virus capability of rice based on D14 protein site editing and application of the method, according to the scheme, an interaction interface of RGSV P3 and rice D14 protein is analyzed through a structural biology means, and it is determined that the 102nd part, with the D14 binding site, of D14 and P3 is aspartic acid (Asp, D). Then, accurate editing of the D14 gene in the rice is realized by utilizing a cytidine base editor (CBE) system, and the site is mutated into asparagine (Asn, N), so that D14 (D102N) transgenic rice is obtained. Disease resistance identification confirms that the mutant has significant resistance to RGSV. Furthermore, a homozygous non-transgenic disease-resistant material which does not contain exogenous transgenic ingredients is obtained through genetic screening and has a good breeding application prospect.

The application provides an antisense oligonucleotide Jag-i9 ASO and application thereof, relates to the technical field of biological medicine, and the antisense oligonucleotide Jag-i9 ASO has the sequence of 5'-ACTGGGCCCTGCACCTGA-3'. By providing the antisense oligonucleotide of a specific sequence, the binding site of target heterogeneous ribonucleoprotein K and the Jag2 gene is targeted, the expression of the pro-inflammatory Jag2 subtype is inhibited, the Jag2 gene splicing site can be accurately targeted, the heterogeneous ribonucleoprotein K binding function is specifically blocked, a targeted intervention means is provided for the treatment of myocardial ischemia-reperfusion injury, the generation of the pro-inflammatory subtype is inhibited by efficiently and accurately regulating the alternative splicing of a specific gene, myocardial cell apoptosis and inflammatory response are reduced, myocardial function is improved, and a new approach is provided for the prevention and treatment of myocardial ischemia-reperfusion injury, the treatment effect is improved, and the advantages of reducing side effects are achieved.

This invention discloses a method and system for predicting RNA binding protein binding sites on RNA without targeting, relating to the field of bioinformatics. The method includes the following steps: acquiring raw RNA structure data; expanding and filtering the preprocessed data; training an RNA analysis model using the filtered data; processing the RNA to be analyzed using the trained RNA analysis model, calculating the probability that each nucleotide is single-stranded, and obtaining a structure score; identifying low-accessibility regions based on the difference between the structure score output by the RNA analysis model and the structure score calculated by the original method; and identifying potential RNA binding protein binding sites by comparing the signal difference with that of the original method in a single RNA structure detection experiment. This invention utilizes the STONE method to improve the accuracy of RNA structure analysis in low-accessibility regions, and uses the improved difference to infer RBP binding sites, thereby improving the accuracy of RBP binding site identification.

This invention relates to an alanine aminotransferase (ALT) detection reagent and its preparation method, belonging to the field of medical testing. The ALT detection reagent comprises nanobodies AC1 and AT1 binding to different ALT binding sites. Nanobodies AC1 are biotinylated and immobilized on an avidin ELISA plate as a capture antibody, while nanobodies AT1 serve as the detection antibody. The ALT detection reagent and method prepared based on these nanobodies can meet the needs for rapid and accurate ALT detection.

Disclosed herein are methods of treating autoimmune, allergic, and / or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and / or inflammatory diseases and depleting the cell.

The present disclosure provides for methods of generating a single stranded primer from an oligonucleotide probe. For instance, the present disclosure is directed to a method of preparing oligonucleotide primers from oligonucleotide probes, such as oligonucleotide probes which have been amplified, and which include a target specific primer sequence, a forward primer binding site, and a reverse primer binding site. It is believed that the presently disclosed method permits the synthesis of thousands to hundreds of thousands and even a million primers in a cost-effective manner, with good yield, in high quantities and at high purity levels.

Methods for increasing expression of a target gene, the method comprising introducing a CCCTC-binding factor (CTCF) binding site (CTCF-BS) into a promoter region of the target gene, e.g., within 500, 250, 200, 150, 100, 50, or 25 nucleotides of the transcription start site (TSS) for the target gene, and optionally expressing in or introducing into the cell a CTCF protein or variant thereof.

The invention provides a method for synthesizing a CMV (cytomegalovirus) promoter and improving the expression quantity of recombinant protein, and belongs to the technical field of gene engineering. The synthetic CMV promoter is based on a CMV promoter, and nucleotide sequences at a transcription factor YY1 binding site are connected in series for 2-7 times; the nucleotide sequence of the CMV promoter is as shown in SEQ ID NO. 1. According to the invention, a transcription factor YY1 and a CMV promoter are subjected to collaborative optimization creatively, the CMV promoter sequence is optimized by analyzing the binding motif of the transcription factor YY1 gene on the CMV promoter sequence, and a plurality of promoter sequences are obtained by connecting binding sites in series. Different experiments prove that the effect of enhancing the activity of the CMV promoter in CHO cells can be achieved, and a new expression element is provided for efficient expression of recombinant protein.

The disclosure provides methods for inhibiting: tyrosinase function and / or regulation or its activity, melanogenesis, melanin production, and cell proliferation of melanomas using compounds described here, or analog(s) thereof, or compositions comprising such compounds or analog(s) thereof in a therapeutically effective amount to bind or occupy any one or more of the tyrosinase binding sites in an amount sufficient to inhibit tyrosinase (i.e., function or regulation) or its activity, inhibit melanogenesis, inhibit melanin production, even out skin pigmentation or skin tone, brighten skin pigmentation or skin tone, inhibit cell proliferation of melanomas, and ameliorate or treat skin cancer (e.g., melanoma) in a subject in need thereof.